1472624-85-3
Chemical Structure
7ACC2
- CAS No.: 1472624-85-3
- Formula:C18H15NO4
- Molecular Weight:309.32
IUPAC Name: 7-(benzyl(methyl)amino)-2-oxo-2H-chromene-3-carboxylic acid
InChIKey: XTKDQPFUOFAMRL-UHFFFAOYSA-N
SMILES: CN(C1=CC=C(C=C(C(O)=O)C(O2)=O)C2=C1)CC3=CC=CC=C3
Biological Activity: 7ACC2 is a potent monocarboxylate transporter (MCT) inhibitor with an IC50 of 11 nM for inhibition of [14C]-lactate influx. 7ACC2 is also a potent inhibitor of mitochondrial pyruvate transport. 7ACC2 is an anticancer agent through inhibition of lactate flux[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
7ACC2 | 99.95% | 7ACC2 is a potent monocarboxylate transporter (MCT) inhibitor with an IC50 of 11 nM for inhibition of [14C]-lactate influx. 7ACC2 is also a potent inhibitor of mitochondrial pyruvate transport. 7ACC2 is an anticancer agent through inhibition of lactate flux. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.73
HY-D00677ACC1 -
Similarity Score 0.67
HY-W0395197-Methoxycoumarin-3-carboxylic acid -
Similarity Score 0.66
HY-175840TAU-IN-5 -
Similarity Score 0.66
HY-W087433Ethyl 7-(diethylamino)-2-oxo-2H-chromene-3-carboxylate -
Similarity Score 0.66
HY-150695hCAIX/XII-IN-5 -
Similarity Score 0.65
HY-W150677BioA-IN-1 -
Similarity Score 0.65
HY-1870213-Carboxyumbelliferyl acetate -
Similarity Score 0.64
HY-W275048MAO-A inhibitor 3 -
Similarity Score 0.64
HY-132907MAO-B-IN-2 -
Explore the MedChemAI to find more analogs
References
- [1]. Draoui N, et al. Synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells. Bioorg Med Chem. 2013 Nov 15;21(22):7107-17. [Content Brief]
- [2]. Cyril Corbet, et al. Interruption of lactate uptake by inhibiting mitochondrial pyruvate transport unravels direct antitumor and radiosensitizing effects. Nat Commun. 2018 Mar 23;9(1):1208. [Content Brief]